Clovis Oncology is a biotechnology & medical research business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 413 staff and has a trailing 12-month revenue of around $133 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.09 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $0.41 |
| 200-day moving average | $1.22 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.08 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.093 from 2023-02-22
| 1 week (2024-07-13) | N/A |
|---|---|
| 1 month (2024-06-20) | N/A |
| 3 months (2024-04-20) | N/A |
| 6 months (2024-01-20) | N/A |
| 1 year (2023-07-20) | N/A |
|---|---|
| 2 years (2022-07-22) | -94.86% |
| 3 years (2021-07-23) | 4.86 |
| 5 years (2019-07-24) | 11.07 |
Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $133 million |
|---|---|
| Gross profit TTM | $115.3 million |
| Return on assets TTM | -30.18% |
| Return on equity TTM | 0% |
| Profit margin | -189.38% |
| Book value | $-2.89 |
| Market Capitalization | $11.8 million |
TTM: trailing 12 months
We're not expecting Clovis Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 0.2205. This would suggest that Clovis Oncology's shares are less volatile than average (for this exchange).
Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U. S. , the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
A deep dive into the highlights and limitations of Frec.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.